Haemostasis and Thrombosis for Surgeons — Clot by Cells, Stop Bleeding by Trial, Reverse by Number

The bleeding trauma patient, the anticoagulated surgical candidate, the oozing coagulopathic field, the heparinised intensive-care patient with falling platelets — one needs TXA within the hour, one needs bridging refused, one needs fibrinogen replaced by trial arithmetic, one needs heparin stopped on a low 4Ts score that actually rules out. The examiner watches you dose by trial, not by habit.^{[4][11][22][26]}

Successful management has six limbs — cell-based physiology with Virchow applied to bleeding, TXA by three trials inside 3 hours with POISE-3 safety honesty, vWD and haemophilia guideline scope, no-routine-bridging with PAUSE interruption arithmetic, reversal by 4F-PCC/idarucizumab/andexanet numbers, and DIC definition with rule-out HIT, bounded viscoelastic, FIBRES replacement, DDAVP niches and DOAC-aware labs — agreed across trials, guidelines and counted cohorts.^{[1][4][8][11][15][20]} The arc fits one sentence: clotting happens on cells in three overlapping stages, TXA 1 g early saves bleeding lives in trauma and postpartum haemorrhage and trims surgical bleeding without proven cardiovascular safety, vWD is managed and diagnosed under four-society guidelines with haemophilia under WFH scope, warfarin interruption needs no routine bridge and DOACs pause by bleed-risk days, VKA reverses faster with 4F-PCC and dabigatran with 5 g idarucizumab and factor-Xa bleeders with andexanet, DIC is a sepsis-or-trauma syndrome scored by ISTH and treated at its cause, low 4Ts rules HIT out, ROTEM guides within honest limits, fibrinogen concentrate matches cryoprecipitate, DDAVP earns its niches, and the lab is read with DOAC interference in mind.^{[1][4][8][11][15][20][22][26][28][30]}

Clotting happens on cells, in three stages — and Virchow cuts both ways

The in-vivo model is cell-based, not a cascade: coagulation is regulated by properties of cell surfaces, and cells with similar phosphatidylserine content can play very different roles in haemostasis depending on their complement of surface receptors.^[1] Coagulation occurs not as a cascade but in three overlapping stages, beginning with initiation on a tissue-factor-bearing cell and proceeding through amplification in which platelets and cofactors are activated.^[1] Date the frameworks honestly: the enzymatic cascade model was first described in the 1960s, the cell-based model integrated cellular coordination into clot enzymology around the turn of the millennium, and current thinking converges on innate-immune activation — with each step forward heralding a revolution in procoagulant and anticoagulant therapeutics.^[2]

Virchow's triad is traditionally invoked to explain pathophysiologic mechanisms leading to thrombosis — concerted roles for abnormalities in blood composition, vessel-wall components, and blood flow in arterial and venous thrombosis — and the same triad organises bleeding when read in reverse.^[3] Composition is the best-studied limb: increased plasma prothrombin and fibrinogen are established thrombosis risk factors, whereas deficiencies in factors VIII and IX produce bleeding as haemophilia A and B respectively; vessel-wall cellular components contribute adhesion molecules recruiting leukocytes and platelets to vascular damage alongside tissue factor.^[3] For the surgeon this means every clot and every ooze gets the same three questions: what is wrong with the blood, what is wrong with the wall, what is wrong with the flow.^[3]

Give TXA early or not at all — three trials, one clock

CRASH-2 randomised 20,211 adult trauma patients with or at risk of significant bleeding across 274 hospitals in 40 countries, assigning within 8 hours of injury to tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8 h) or matching placebo, with all analyses by intention to treat.^[4] All-cause mortality fell from 16.0 to 14.5 percent (1,613 of 10,067 placebo against 1,463 of 10,060 TXA; relative risk 0.91, interval 0.85 to 0.97; P equals 0.0035), and death due to bleeding fell from 5.7 to 4.9 percent (574 against 489; relative risk 0.85, interval 0.76 to 0.96; P equals 0.0077).^[4]

WOMAN randomised 20,060 women aged 16 and over with clinical postpartum haemorrhage after vaginal or caesarean birth across 193 hospitals in 21 countries to 1 g intravenous TXA or matching placebo plus usual care, with a conditional second gram if bleeding continued after 30 minutes or restarted within 24 hours.^[5] Death due to bleeding fell from 1.9 to 1.5 percent (191 of 9,985 placebo against 155 of 10,036 TXA; risk ratio 0.81, interval 0.65 to 1.00; P equals 0.045), and in women treated within 3 hours of birth from 1.7 to 1.2 percent (127 against 89; risk ratio 0.69, interval 0.52 to 0.91; P equals 0.008) — but hysterectomy was not reduced (3.5 against 3.6 percent; risk ratio 1.02) and the composite of death or hysterectomy did not move.^[5] Thromboembolic adverse events did not differ significantly between groups.^[5]

POISE-3 randomised 9,535 noncardiac-surgery patients to 1-g intravenous bolus TXA or placebo at the start and end of surgery: the composite bleeding outcome (life-threatening, major, or critical-organ bleeding at 30 days) fell from 11.7 to 9.1 percent (561 of 4,778 placebo against 433 of 4,757 TXA; hazard ratio 0.76, interval 0.67 to 0.87; absolute difference minus 2.6 points).^[6] Safety is where honesty matters: the composite cardiovascular outcome ran 13.9 against 14.2 percent (639 against 649; hazard ratio 1.02, interval 0.92 to 1.14), and although the between-group difference was small, the noninferiority of tranexamic acid was not established.^[6] Quote POISE-3 as bleeding benefit with unproven cardiovascular safety — never as proof of safety.^[6]

The clock disciplines all three trials: give TXA immediately and only within 3 hours of injury, because the relative reduction in 24-hour mortality is greatest within 2 hours and decreases rapidly thereafter — shown across 28,448 CRASH-2 and CRASH-3 trauma patients by causal-forest modelling.^[7] For the viva: under 2 hours is best, under 3 hours is indicated, beyond 3 hours is not.^[7]

Inherited bleeding is guideline scope, not memorised numbers

Von Willebrand disease is a common inherited bleeding disorder — the most common inherited bleeding disorder known in humans — with significant variability in what management clinicians offer, which is why four societies (ASH, ISTH, NHF, WFH) convened a multidisciplinary guideline panel with patient representation under GRADE methodology and systematic evidence reviews through November 2019 for management and to 8 January 2020 for diagnosis.^[8][9] Cite the guidelines as the decision framework for VWD workup and management choices; the specifics of replacement, DDAVP candidacy and procedural cover belong to the guideline text and local haematology, not to a memorised shortcut.^[8]

Haemophilia scope is the WFH 3rd-edition guideline (Srivastava and colleagues, Haemophilia 2020) — the verified reference for factor-VIII/IX-deficient bleeding management.^[10] The physiology behind it is Virchow in reverse: deficiencies in plasma factors VIII and IX result in bleeding as haemophilia A and B respectively.^[3] Where desmopressin applies, it applies nontransfusionally: DDAVP raises circulating factor VIII and von Willebrand factor and treats mild and moderate haemophilia and von Willebrand disease without transfusion.^[28]

Stop bridging routinely, pause DOACs by bleed-risk days

BRIDGE ended routine bridging. In 1,884 atrial-fibrillation patients with warfarin interrupted for elective operations or invasive procedures — warfarin stopped 5 days before, resumed within 24 hours after, randomised to dalteparin 100 IU per kg twice daily or matching placebo from 3 days pre-procedure to 5–10 days post-procedure — arterial thromboembolism ran 0.4 percent without bridging against 0.3 percent with bridging (risk difference 0.1 points, interval minus 0.6 to 0.8; noninferior), while major bleeding ran 1.3 against 3.2 percent (relative risk 0.41, interval 0.20 to 0.78; superior).^[11] Forgoing bridging prevents embolism just as well and bleeds less — the default is no bridge.^[11]

The BRIDGE bleeding analysis tells you who still bleeds: among 1,813 analysed patients (895 bridged, 918 placebo) with median age 72.6 years, 41 major bleeds occurred at median postoperative day 7.0 (interquartile range 4.0 to 18.0) — and bridging itself was a baseline predictor of major bleeding with odds ratio 2.4 (interval 1.2 to 4.8), alongside renal history.^[12] A bleed on day 7 in a bridged, renally impaired patient is the predictable failure, not bad luck.^[12]

PAUSE gives the DOAC arithmetic: 3,007 atrial-fibrillation patients on long-term apixaban (41.8 percent), dabigatran (22.2 percent) or rivaroxaban (36.0 percent) across 23 centres in Canada, the United States and Europe, omitting the DOAC 1 day before low-bleed-risk procedures and 2 days before high-bleed-risk procedures, resuming 1 day after low-risk and 2 to 3 days after high-risk procedures with no heparin bridging and no coagulation-function testing.^[13] Thirty-day major bleeding ran 1.35 percent (apixaban), 0.90 percent (dabigatran) and 1.85 percent (rivaroxaban); arterial thromboembolism ran 0.16, 0.60 and 0.37 percent respectively — rising to about 3 percent major bleeding (2.96 apixaban, 2.95 rivaroxaban) after high-bleed-risk procedures.^[13]

Fence the high-risk and neuraxial case honestly: uncertainty remains for elective high-bleed-risk surgery including neuraxial and deep nerve blocks, where the PAUSE-2 pilot randomised 159 patients (86 apixaban, 12 dabigatran, 61 rivaroxaban) between ASRA-based and PAUSE-based perioperative strategies to generate preliminary residual-level data and feasibility for a larger trial.^[14] Quote PAUSE-2 as a pilot, not a protocol.^[14]

Reverse by number: 4F-PCC, idarucizumab, andexanet

For urgent VKA reversal before surgery or invasive procedures, 4F-PCC beats plasma. In 181 randomised patients (90 to weight-and-INR-dosed 4F-PCC plus vitamin K, 91 to plasma plus vitamin K; 168 in efficacy analysis), effective haemostasis reached 90 against 75 percent (78 of 87 against 61 of 81; difference 14.3 points, interval 2.8 to 25.8) and rapid INR reduction to 1.3 or below at half an hour reached 55 against 10 percent (48 against 8; difference 45.3 points, interval 31.9 to 56.4) — noninferior then superior on both endpoints.^[15] Price the harm alongside: thromboembolic events in 7 against 8 percent (6 against 7 patients), with fewer fluid-overload events on PCC (3 against 13 percent).^[15]

Dabigatran reverses with 5 g intravenous idarucizumab: across 503 multicentre open-label patients (301 uncontrolled bleeding, 202 urgent procedures), median maximum reversal hit 100 percent (interval 100 to 100) by dilute thrombin or ecarin clotting time, and among assessable bleeders the median time to bleeding cessation was 2.5 hours.^[16] The surgical subgroup is what the surgeon quotes: 202 patients received idarucizumab before surgery or procedures spanning 49 abdominal, 45 orthopaedic, 34 vascular, 8 neurologic and 4 genitourinary operations plus catheter, drainage and diagnostic cases — reversal within minutes in almost all, normal haemostasis in over 91 percent.^[17]

Factor-Xa bleeders reverse with andexanet alfa: in the ANNEXA-4 final report, evaluable apixaban patients fell from median 146.9 to 10.0 ng/mL anti-FXa activity and rivaroxaban patients from 214.6 to 10.8 ng/mL, with excellent or good haemostatic efficacy in 274 of 342 evaluable patients (80 percent, interval 75 to 84).^[18] The price is thrombosis in 50 of the safety population (10 percent), with none occurring after oral anticoagulation restart — and anti-FXa reduction predicted haemostatic efficacy in intracranial haemorrhage.^[18] Reverse, then restart anticoagulation as soon as the bleeding indication allows.^[18]

DIC is a syndrome of its cause; HIT is ruled out, not in

Disseminated intravascular coagulation is an acquired syndrome of widespread intravascular coagulation activation, triggered by infectious insults such as sepsis and non-infectious insults such as trauma — driven by cytokine-initiated tissue-factor coagulation, failed anticoagulant control and PAI-1 fibrinolysis suppression into endothelial dysfunction and microvascular thrombosis.^[20] The ISTH established a diagnostic scoring system built from global haemostatic test parameters, now well validated across diverse clinical settings; the definition, criteria and scoring originate with Taylor and colleagues (2001).^[19][20] Management cornerstone first: specific and vigorous treatment of the underlying condition, with DIC managed simultaneously — never anticoagulate the score while ignoring the sepsis or the crushed tissue.^[20]

JSEPTIC-DIC counts the syndrome in sepsis: among 1,895 patients across 42 Japanese intensive-care units, JAAM criteria diagnosed 1,162 (61 percent) and ISTH criteria 554 (29 percent); DIC patients died more often in hospital (33 against 20 percent by JAAM, 38 against 24 percent by ISTH), though neither score independently predicted mortality in multivariable analysis.^[21] Use the counts to respect the syndrome's lethality without overselling the score as an independent predictor.^[21]

Heparin-induced thrombocytopenia is a rule-out diagnosis. Across 13 studies and 3,068 suspected-HIT patients, 1,712 (55.8 percent) scored low-probability on 4Ts, and the negative predictive value of a low score ran 0.998 (interval 0.970 to 1.000) regardless of scorer, prevalence or setting.^[22] A low 4Ts score lets heparin continue; anything higher needs immunoassay and non-heparin anticoagulation while serotonin-release assay pends.^[22] The prospective combination strategy proves the workflow: in 526 participants with 4Ts, rapid PF4/heparin particle-gel immunoassay and serotonin-release assay, low-4Ts patients (any PaGIA) or intermediate-4Ts with negative PaGIA stayed on prophylactic danaparoid or fondaparinux while the rest received therapeutic non-heparin anticoagulation — with 6 management failures (1.1 percent, interval 0.2 to 2.1), and a negative PaGIA cutting pretest probability from 1.9 percent to zero.^[23]

Guide resuscitation viscoelastically within limits, replace fibrinogen by trial, read the lab with DOACs in mind

Trauma-induced coagulopathy on admission predicts death, transfusion burden, complications and longer critical care — and conventional testing (PT ratio/INR, aPTT, full blood count) remains the reference most centres use.^[24] Cochrane's diagnostic review of TEG/ROTEM for trauma-induced coagulopathy (search to March 2013 across MEDLINE, EMBASE and eleven further databases) found only three small studies (UK, France, Afghanistan; civilian and military): ROTEM clot-amplitude accuracy pairs ran sensitivity 70 with specificity 86 percent at 5 minutes, 100 with 70 percent at 10 minutes, and 88 with 100 percent at 15 minutes — but reference-standard bias was high and index-test bias high or unclear, so the numbers may mislead.^[24] Quote viscoelastic accuracy with its bias warning attached, never bare.^[24]

Surgical ROTEM thresholds exist for massive-transfusion risk: among 222 trauma activations (37 requiring massive transfusion, 17 percent, more severely injured), EXTEM clotting time ran 87 against 64 seconds, EXTEM angle 54 against 69 degrees, 10-minute clot amplitude 30.5 against 50 mm, and 60-minute lysis index 47 against 94 percent in MT against non-MT patients.^[25] Use these as resuscitation triggers within a goal-directed algorithm, not as transfusion prescriptions on their own.^[25]

Fibrinogen replacement is a noninferiority story. Acquired hypofibrinogenaemia (fibrinogen below 1.5 to 2.0 g/L) causes surgical bleeding, and guidelines recommend cryoprecipitate or fibrinogen concentrate — FIBRES randomised 827 bleeding cardiac-surgery patients at median 1.6 g/L (4 g concentrate in 415, 10 units cryoprecipitate in 412) and found 24-hour post-bypass allogeneic transfusion means of 16.3 against 17.0 units (ratio 0.96; noninferior, not superior), with thromboembolism in 7.0 against 9.6 percent (26 against 35 patients).^[26] The Astana replication in 88 patients under 2.0 g/L (1.40 g concentrate against 9.33 units cryoprecipitate) raised fibrinogen by 96 against 125 mg/dL at 24 hours.^[27] Concentrate matches cryoprecipitate — choose by availability, logistics and local protocol.^[26][27]

Desmopressin earns two niches. As physiology: DDAVP raises factor VIII and von Willebrand factor, shortens the prolonged bleeding time of uraemia, liver cirrhosis and platelet dysfunction, and reduces blood loss and transfusion where losses run unusually large.^[28] As trial: in 59 massive-haemorrhage gastrointestinal-surgery patients across three hospitals (0.3 ug/kg DDAVP against saline), 24-hour haemoglobin fall ran minus 5.0 against minus 10.2 g/L (P equals 0.03) with higher Sonoclot platelet function (2.56 against 1.91) and no creatinine or urine-volume difference.^[29]

Read an isolated prolonged APTT — normal PT/INR alongside — by algorithm: lupus anticoagulant (common), heparin exposure, or specific factor deficiency (rare), because reagents differ in factor sensitivity and surgery may need postponing until the cause is established.^[30] In the DOAC era, expect interference: across 1,035 mixing studies (2017–2021), mixing corrected most prolonged PT samples (93 percent) but 32 showed incomplete correction — 18 confounded by DOACs, 3 by factor-V inhibitor — and the post-incubation aPTT prolongation once thought characteristic of specific inhibitors splits evenly across lupus anticoagulant (28 percent), DOAC (25 percent) and true inhibitors (28 percent).^[31] Check the medication list before the mixing study, not after.^[31]

Fenced neighbours, named so the examiner sees you know the borders: red-cell thresholds and restrictive-versus-liberal strategy belong to the transfusion-coagulation topic; venous-thromboembolism treatment belongs to dvt-pe-surgical; balanced blood-product ratios belong to massive-transfusion; and the ISTH overt-DIC point arithmetic is deliberately not stated here because no fetched abstract carries its components — quote the validated system and the JSEPTIC counts, not a remembered cutoff.^[20][21]

20,211 trauma patients, 1 g over 10 min then 1 g over 8 h within 8 h of injury; all-cause 14.5 vs 16.0% RR 0.91, bleeding death 4.9 vs 5.7% RR 0.85 (PMID 20554319).^[4] 20,060 PPH, 1 g IV plus usual care with a conditional second gram; bleeding death 1.5 vs 1.9% RR 0.81, within-3 h 1.2 vs 1.7% RR 0.69; hysterectomy NOT reduced (PMID 28456509).^[5] Price POISE-3 exactly: 9,535 noncardiac-surgery patients, 1 g at start and end; bleeding composite 9.1 vs 11.7% HR 0.76, cardiovascular noninferiority NOT established HR 1.02 (PMID 35363452).^[6]

References31ShowHide

1. [1]Hoffman M, et al. A cell-based model of hemostasis. Thromb Haemost, 2001.PMID 11434702
2. [2]Yong J, et al. Rethinking coagulation: from enzymatic cascade and cell-based reactions to a convergent model involving innate immune activation. Blood, 2023.PMID 37890148
3. [3]Wolberg AS, et al. Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited. Anesth Analg, 2012.PMID 22104070
4. [4]Shakur H, Roberts I, Bautista R et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet, 2010.PMID 20554319
5. [5]WOMAN Trial Collaborators, et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet, 2017.PMID 28456509
6. [6]Devereaux PJ, et al. Tranexamic Acid in Patients Undergoing Noncardiac Surgery. N Engl J Med, 2022.PMID 35363452
7. [7]Osawa I, et al. Tranexamic acid for trauma: optimal timing of administration based on the CRASH-2 and CRASH-3 trials. Br J Surg, 2025.PMID 40277024
8. [8]Connell NT, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv, 2021.PMID 33570647
9. [9]James PD, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv, 2021.PMID 33570651
10. [10]Srivastava A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 2020.PMID 32744769
11. [11]Douketis JD, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med, 2015.PMID 26095867
12. [12]Clark NP, et al. Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial. Am Heart J, 2018.PMID 29224638
13. [13]Douketis JD, et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med, 2019.PMID 31380891
14. [14]Douketis JD, et al. Perioperative management of direct oral anticoagulants in patients having a high-bleed-risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE)-2 pilot randomized trial. J Thromb Haemost, 2025.PMID 40086754
15. [15]Goldstein JN, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet, 2015.PMID 25728933
16. [16]Pollack CV Jr, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med, 2017.PMID 28693366
17. [17]Levy JH, et al. Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study. Ann Surg, 2021.PMID 31599808
18. [18]Milling TJ Jr, et al. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Circulation, 2023.PMID 36802876
19. [19]Taylor FB Jr, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost, 2001.PMID 11816725
20. [20]Gando S, et al. Disseminated intravascular coagulation. Nat Rev Dis Primers, 2016.PMID 27250996
21. [21]Saito S, et al. Epidemiology of disseminated intravascular coagulation in sepsis and validation of scoring systems. J Crit Care, 2019.PMID 30471557
22. [22]Cuker A, et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood, 2012.PMID 22990018
23. [23]Linkins LA, et al. Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood, 2015.PMID 25926600
24. [24]Hunt H, et al. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma induced coagulopathy in adult trauma patients with bleeding. Cochrane Database Syst Rev, 2015.PMID 25686465
25. [25]Stettler GR, et al. Rotational thromboelastometry thresholds for patients at risk for massive transfusion. J Surg Res, 2018.PMID 29907206
26. [26]Callum J, et al. Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial. JAMA, 2019.PMID 31634905
27. [27]Ayaganov D, et al. Prospective, Randomized Study of Fibrinogen Concentrate Versus Cryoprecipitate for Correcting Hypofibrinogenemia in Cardiac Surgery Patients. J Cardiothorac Vasc Anesth, 2024.PMID 38016817
28. [28]Mannucci PM, et al. Desmopressin: a nontransfusional hemostatic agent. Annu Rev Med, 1990.PMID 2184748
29. [29]Wang LC, et al. Desmopressin acetate decreases blood loss in patients with massive hemorrhage undergoing gastrointestinal surgery. Turk J Gastroenterol, 2020.PMID 32721919
30. [30]Rasmussen KL, et al. Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review. Eur J Haematol, 2020.PMID 32049377
31. [31]Kim MJ, et al. Interpreting coagulation mixing study results in the era of direct oral anticoagulants. Blood Coagul Fibrinolysis, 2024.PMID 37994629